One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been described ...

The US Food and Drug Administration (FDA) has updated its seven-year-old guidance to clarify the differences among abbreviated approval pathways and the data it will accept for these applications.

Since application begins 9 or 13 years after new drug approval, Mounjaro and Zepbound are also future candidates. These two are linked to the third risk. To maintain growth while unit prices continue ...

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbuster ...

LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early ...

(1) Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to $0.14 in Q2 2025 A discussion of the non-GAAP financial measures is included below under "Reconciliation of ...

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

We’re glad you’re considering Bethel. Applying only takes a few steps, and there’s no application fee. First-year students have the option to apply using the Bethel application or the Common App.